<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101437</url>
  </required_header>
  <id_info>
    <org_study_id>TCHIRB-I021003</org_study_id>
    <nct_id>NCT02101437</nct_id>
  </id_info>
  <brief_title>The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei City Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei City Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we
      will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the basis
      of medical criteria (clinical guidelines) routine as aspirin + clopidogrel or aspirin +
      ticagrelor, according to medical guidelines currently no other disposal alternative proposal
      (unless adverse drug tolerance or bleeding can not be administered); idea of this experiment
      for acute coronary syndrome or conventional cardiac catheterization after stenting, platelet
      miRNA expression (miR-96 , miR-200b, miR-495, miR-107) after cardiac catheterization and
      interventional treatment of clopidogrel or ticagrelor acceptance of platelet reactivity (PRU)
      correlation values (given clopidogrel or ticagrelor determined by the clinician, the patient
      follow-up experiment to track only and observation), aims to explore under different platelet
      reactivity (hyper-reactive or hypo-reactive), their differences in miRNA performance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">November 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>miRNA</measure>
    <time_frame>7 days</time_frame>
    <description>miRNA-365-3p measure by Roche miRNA kits; PRP(platelet riched plasma) isolated miRNA by isolation Kit, then havest in cDNA synthesis Kit; then perform RT PCR.
.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>PRU</condition>
  <condition>miRNA</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects received clopidogrel 75mg qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects received ticagrelor 90mg qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects received cilostazol 100mg bid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>miRNA within 24hr</intervention_name>
    <description>miRNA within 24hr</description>
    <arm_group_label>cilostazol</arm_group_label>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>miRNA after 1 week</intervention_name>
    <description>miRNA after 1 week</description>
    <arm_group_label>cilostazol</arm_group_label>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>miRNA after 1 month</intervention_name>
    <description>miRNA after 1 month</description>
    <arm_group_label>cilostazol</arm_group_label>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1 under DAPT (dual antiplatelet therapy) of stable angina patients for elective stent
        implantation.

        2. DAPT 24 hours after treatment PRU (platelet activity units) values. (Drug unresponsive
        patients was defined as PRU&gt; 235).

        Exclusion Criteria:

        1.Not suitable for the treatment of patients with DAPT. (Active peptic ulceration or
        bleeding) 2 patients of aspirin, clopidogrel, ticagrelor, cilostazol medication
        intolerance.

        3 contraindications for aspirin, clopidogrel, ticagrelor, cilostazol drug usage (such as
        heart failure patients not suitable for use cilostazol).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chen yueh chung, chieft</last_name>
    <role>Principal Investigator</role>
    <affiliation>taipei city hospital cardiovascular section</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei city hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2014</study_first_posted>
  <results_first_submitted>November 11, 2017</results_first_submitted>
  <results_first_submitted_qc>August 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei City Hospital</investigator_affiliation>
    <investigator_full_name>Yueh-Chung, Chen</investigator_full_name>
    <investigator_title>chief of ICU</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>no stent or anti-platelet drugs</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel</title>
          <description>under clopidogrel treatment</description>
        </group>
        <group group_id="P3">
          <title>Ticagrelor</title>
          <description>under ticagrelor treatment</description>
        </group>
        <group group_id="P4">
          <title>Clopidogrel+Cilostazol</title>
          <description>under clopidogrel and cilostazol treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>receive different anti-platelet drugs</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>no stent or anti-platelet drugs</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel</title>
          <description>under clopidogrel treatment</description>
        </group>
        <group group_id="B3">
          <title>Ticagrelor</title>
          <description>under ticagrelor treatment</description>
        </group>
        <group group_id="B4">
          <title>Clopidogrel+Cilostazol</title>
          <description>under clopidogrel and cilostazol treatment</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.67" spread="9.81"/>
                    <measurement group_id="B2" value="66.39" spread="10.68"/>
                    <measurement group_id="B3" value="67.99" spread="13.56"/>
                    <measurement group_id="B4" value="65.35" spread="11.55"/>
                    <measurement group_id="B5" value="66.59" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>miRNA</title>
        <description>miRNA-365-3p measure by Roche miRNA kits; PRP(platelet riched plasma) isolated miRNA by isolation Kit, then havest in cDNA synthesis Kit; then perform RT PCR.
.</description>
        <time_frame>7 days</time_frame>
        <population>check miRNA expression: Normalized expression level=2 -Ct, which means the more amount of miRNA, the less Ct.
Negative valure indicated expression&lt;1, and calculated after log2; the final was fold change expression of miRNA-365-3p compared to the control sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>no stent or anti-platelet drugs</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>under clopidogrel treatment</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor</title>
            <description>under ticagrelor treatment</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel+Cilostazol</title>
            <description>under clopidogrel and cilostazol treatment</description>
          </group>
        </group_list>
        <measure>
          <title>miRNA</title>
          <description>miRNA-365-3p measure by Roche miRNA kits; PRP(platelet riched plasma) isolated miRNA by isolation Kit, then havest in cDNA synthesis Kit; then perform RT PCR.
.</description>
          <population>check miRNA expression: Normalized expression level=2 -Ct, which means the more amount of miRNA, the less Ct.
Negative valure indicated expression&lt;1, and calculated after log2; the final was fold change expression of miRNA-365-3p compared to the control sample.</population>
          <units>fold of change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.14" lower_limit="-8.48" upper_limit="-7.61"/>
                    <measurement group_id="O2" value="-3.46" lower_limit="-5.1" upper_limit="-0.63"/>
                    <measurement group_id="O3" value="-7.54" lower_limit="-8.27" upper_limit="-6.81"/>
                    <measurement group_id="O4" value="-3.97" lower_limit="-5.26" upper_limit="-3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>no stent or anti-platelet drugs</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel</title>
          <description>under clopidogrel treatment</description>
        </group>
        <group group_id="E3">
          <title>Ticagrelor</title>
          <description>under ticagrelor treatment</description>
        </group>
        <group group_id="E4">
          <title>Clopidogrel+Cilostazol</title>
          <description>under clopidogrel and cilostazol treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>chen yueh-chung</name_or_title>
      <organization>taipei city hospital</organization>
      <phone>88627093600 ext 3741</phone>
      <email>chenyuehchung.tw@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

